|
|
|
|
β2-adrenoceptor
|
|
|
Hs |
Agonist |
Partial agonist |
10.6 – 11.4 |
pKd |
- |
3,5,9-10 |
|
| ⤷ |
pKd
10.6 – 11.4
[3,5,9-10]
|
|
β2-adrenoceptor
|
|
|
Hs |
Antagonist |
Partial agonist |
10.6 – 11.4 |
pKd |
- |
3,5,9-10 |
|
| ⤷ |
pKd
10.6 – 11.4
It is necessary to use an excess of a β1-adrenoceptor-selective ligand such as CGP20712A in combination with this radioligand in order to allow visualisation of β2-adrenoceptor binding in native tissues.
[3,5,9-10]
|
|
β1-adrenoceptor
|
|
|
Hs |
Antagonist |
Partial agonist |
10.4 – 11.3 |
pKd |
- |
3-5,9 |
|
| ⤷ |
pKd
10.4 – 11.3
It is necessary to use an excess of a β2-AR-selective ligand such as ICI 118551 in combination with this radioligand in order to allow visualisation of β1-AR binding in native tissue.
[3-5,9]
|
|
β1-adrenoceptor
|
|
|
Hs |
Agonist |
Partial agonist |
10.4 – 10.8 |
pKd |
- |
2-5,8-9 |
|
| ⤷ |
pKd
10.4 – 10.8
[2-5,8-9]
|
|
β3-adrenoceptor
|
|
|
Hs |
Agonist |
Partial agonist |
9.0 – 9.8 |
pKd |
- |
1,5-7,9 |
|
| ⤷ |
pKd
9.0 – 9.8
[1,5-7,9]
|
|
β3-adrenoceptor
|
|
|
Hs |
Antagonist |
Partial agonist |
9.0 – 9.8 |
pKd |
- |
1,5-7,9 |
|
| ⤷ |
pKd
9.0 – 9.8
[1,5-7,9]
|
|
β3-adrenoceptor
|
|
|
Mm |
Agonist |
Partial agonist |
9.3 – 9.4 |
pKd |
- |
7 |
|
| ⤷ |
pKd
9.3 – 9.4
[7]
|
|